Hansen, Per From; Jørgensen, Mogens; Kjeldgaard, Niels Ole; Ploug, Jørgen
August 1961
Angiology;Aug1961, Vol. 12 Issue 8, p367
Academic Journal
It is possible to give urokinase intravascularly, even in large doses, without major side effects. These injections are seen to give rise to a strong fibrinolytic activity in the blood, In the dogs an afibrinogenemia sometimes was observed. Parenchymatous bleedings were never seen with the doses given, neither in men or in dogs. No clear cut therapeutic effect could be demonstrated except in patients with superficial thrombophlebitis, in whom a transient improvement was seen.


Related Articles

  • A novel urokinase receptor-targeted inhibitor for plasmin and matrix metalloproteinases suppresses vein graft disease. Eefting, Daniel; Seghers, Leonard; Grimbergen, Jos M.; De Vries, Margreet R.; De Boer, Hetty C.; Lardenoye, Jan-Willem H.P.; Jukema, J. Wouter; Bockel, J. Hajo van; Quax, Paul H.A. // Cardiovascular Research;Nov2010, Vol. 88 Issue 2, p367 

    Aims Matrix metalloproteinases (MMP) and plasminogen activator (PA)/plasmin-mediated proteolysis, especially at the cell surface, play important roles in matrix degeneration and smooth muscle cell migration, which largely contributes to vein graft failure. In this study, a novel hybrid protein...

  • THEORETICAL AND PRACTICAL ASPECTS OF THROMBOLYTIC THERAPY. Hirsh, J. // Angiology;Jan1977, Vol. 28 Issue 1, p1 

    Provides some insights into the theoretical and practical aspects of thrombolytic therapy. Feasibility of producing the dissolution of thrombi and emboli by the plasminogen activators streptokinase and urokinase; Production of fibrinolysis by the plasminogen activators by converting the...

  • Keratinocyte Urokinase-Type Plasminogen Activator is Secreted as a Single Chain Precursor. Koji Hashimoto; Prystowsky, Janet H.; Baird, Janet; Lazarus, Gerald S.; Jensen, Pamela J. // Journal of Investigative Dermatology;Jun88, Vol. 90 Issue 6, p823 

    Urokinase-type plasminogen activator (uPA) is produced and secreted by cultured human keratinocytes as a single chain precursor. UPA in keratinocyte conditioned medium is not susceptible to inhibition with diisopropylfluorophosphate (DFP), and it has an apparent molecular weight of 55 kD under...

  • PEGylated DX-1000: Pharmacokinetics and Antineoplastic Activity of a Specific Plasmin Inhibitor. Devy, Laetitia; Rabbani, Shafaat A.; Stochl, Mark; Ruskowski, Mary; Mackie, Ian; Naa, Laurent; Toews, Mark; Van Gool, Reinoud; Chen, Jie; Ley, Art; Ladner, Robert C.; Dransfield, Daniel T.; Henderikx, Paula // Neoplasia;Nov2007, Vol. 9 Issue 11, p927 

    Novel inhibitors of the urokinase-mediated plasminogen (plg) activation system are potentially of great clinical benefit as anticancer treatments. Using phage display, we identified DX-1000 a tissue factor pathway inhibitor-derived Kunitz domain protein which is a specific high-affinity...

  • A Bi-Functional Anti-Thrombosis Protein Containing Both Direct-Acting Fibrin(ogen)olytic and Plasminogen-Activating Activities. Hailong Yang; Yipeng Wang; Yao Xiao; Ying Wang; Jing Wu; Cunbao Liu; Huahu Ye; Fengliang Li; Haining Yu; Lai, Ren // PLoS ONE;2011, Vol. 6 Issue 3, p1 

    Direct-acting fibrin(ogen)olytic agents such as plasmin have been proved to contain effective and safety thrombolytic potential. Unfortunately, plasmin is ineffective when administered by the intravenous route because it was neutralized by plasma antiplasmin. Direct-acting fibrin(ogen)olytic...

  • Negative regulation of urokinase-type plasminogen activator production through FGF-2-mediated activation of phosphoinositide 3-kinase. Mochizuki, Yasushi; Tsuda, Satoshi; Kanetake, Hiroshi; Kanda, Shigeru // Oncogene;10/10/2002, Vol. 21 Issue 46, p7027 

    Presents a study that examined the signal transduction pathways involved in the regulation of urokinase-type plasminogen activator (uPA) production by fibroblast growth factor (FGF)-2 treatment. Upregulation of uPA production in murine brain capillary endothelial cells; Enhancement of...

  • DOES UPA ACTIVITY INCREASE AFTER PARTIAL HEPATECTOMY IN HUMANS? Smith, K.A.; Majeed, A.W.; Mangnall, D. // Gut;Apr2003 Supplement 1, Vol. 52, pA104 

    Introduction: An increase in the activity of the urokinase like plasminogen activator (uPA) has been recorded almost immediately after partial hepatectomy in rats but not confirmed in humans. Aims: To determine whether changes in uPA activity occur in humans immediately after hepatectomy....

  • Correction.  // Gut;Sep2015, Vol. 64 Issue 9, p1465 

    A correction to the article "The urokinase plasminogen activator receptor (uPAR) controls macrophage phagocytosis in intestinal inflammation" that was published in a previous issue is presented.

  • The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy. Ulisse, Salvatore; Baldini, Enke; Sorrenti, Salvatore; D'Armiento, Massimino // Current Cancer Drug Targets;Feb2009, Vol. 9 Issue 1, p32 

    The urokinase plasminogen activator (uPA) system (uPAS) consists of the uPA, its cognate receptor (uPAR) and two specific inhibitors, the plasminogen activator inhibitor 1 (PAI-1) and 2 (PAI-2). The uPA converts the proenzyme plasminogen in the serine protease plasmin, involved in a number of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics